Research and Markets: Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update 2015: 351 companies plus partners developing 502 targeting drugs in 2115 developmental projects

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/b6gw8k/targeting_focal) has announced the addition of the "Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update 2015" report to their offering.

Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins.

There are today 351 companies plus partners developing 502 focal adhesion targeting drugs in 2115 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 301 drugs.

Targeting Focal Adhesion For The Treatment Of Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 244 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 238 out of the 240 studied drug targets so far have been recorded with somatic mutations.

The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 52 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Pipeline Breakdown According to Number of Drugs

• Marketed - 43
• Pre-registration - 4
• Phase III - 69
• Phase II - 193
• Phase I - 248
• Preclinical - 271
• No Data - 12
• Suspended - 5
• Ceased - 301

Delivery Format: Desktop App plus Online Access to Updates (One Year)

For more information visit http://www.researchandmarkets.com/research/b6gw8k/targeting_focal